Chen Cheng
Xuzhou Medical College
9 Papers
6 Citations
Chen Cheng is an academic researcher from Xuzhou Medical College. The author has contributed to research in topics: Lung cancer & Lung microbiome. The author has an hindex of 6, co-authored 8 publications.
Chat about Author
Papers
Interactions of commensal and pathogenic microorganisms with the mucus layer in the colon.
TL;DR: The structures and functions of the mucus layer are described, several crucial influencing factors are expound, including diet styles, medications and host genetics, and how pathogenic microorganisms interact with the mucUS layer and commensal microbiota are discussed, with the understanding that unraveling their complex interactions under homeostatic and dysbiosis conditions in the colon would help reveal some underlying pathogenic mechanisms.
73
Characterization of the lung microbiome and exploration of potential bacterial biomarkers for lung cancer.
Chen Cheng,Zhifeng Wang,Jingqiao Wang,Chao Ding,Chuang Sun,Pingli Liu,Xiaoqiang Xu,Yanan Liu,Bi Chen,Bing Gu +9 more
TL;DR: Differences existed in the lung microbiome of patients with lung cancer and those with benign pulmonary diseases, and some certain bacteria may have potential to predict lung cancer, though future larger-sample studies are required to validate this supposition.
Human infection caused by Streptococcus suis serotype 2 in China: report of two cases and epidemic distribution based on sequence type
TL;DR: The results enhanced the understanding of the ability to cause life-threatening infections in humans and the distribution and evolution of the S. suis in China and several novel STs were successfully discovered in different provinces.
Microbiota dysbiosis in lung cancer: evidence of association and potential mechanisms
TL;DR: It is confirmed that, compared with healthy people, patients with lung cancer show changes in the relative abundance of multiple genera, and innovative strategies for early prevention and personalized treatment of lung cancer are provided.
Teasaponin Ameliorates Murine Colitis by Regulating Gut Microbiota and Suppressing the Immune System Response.
TL;DR: It is demonstrated that TS ameliorated murine colitis through the modulation of immune response, mucus barrier and gut microbiota, thus improving gut dysbiosis and providing a promising perspective on the clinical treatment of IBD.